Spyretherapeutics Is A Clinical Stagebiotechnology Company Dedicated To Developing Innovativetherapeutics For Inflammatory Bowel Diseaseibd Including Ulcerativecolitisucand Crohnaes Diseasecd As Well As Other Immunemediated Conditions Likerheumatoid Arthritisra Thecompany Utilizes Advanced Antibody Engineering And Doseoptimization To Enhancetreatment Efficacy And Conveniencespyres Pipelinefeatures Several Promising Monoclonal Antibody Candidatesincluding Spy001Spy002And Spy00 Spy001 Targets I 4I 7 Integrin And Has Shown Potential For Less Frequent Dosing In Early Studiesspy002 Is A High Potency Anti Tl1A Antibodywith Further Data Expected In 2025Whilespy00 Targets Il 2 With Results Anticipated In Late2025Thecompany Plans To Conduct A Phase2 Study In Ucevaluating Thesecandidates And Their Combinations Under A Singleprotocolwith Initial Results Expected In 2026Headquartered In Walthammassachusettsand Austintexasspyreis Focused On Addressing Theneeds Of Ibd And Ra Patients
No conferences found for this company.
| Company Name | Aeglea Biotherapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
